Meeting
2014 ASCO Annual Meeting
Obesity and the odds of weight gain following androgen deprivation therapy for prostate cancer: Toward a risk adapted approach for ADT use.
Authors
Lior Zvi Braunstein
Harvard Radiation Oncology Program, Boston, MA
Lior Zvi Braunstein , Ming-Hui Chen , Marian J. Loffredo , Philip W. Kantoff , Anthony Victor D'Amico
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00116220
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 5045)
DOI
10.1200/jco.2014.32.15_suppl.5045
Abstract #
5045
Poster Bd #
174
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Duration of the anti-androgen in men undergoing six months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.
First Author: Nina Niu Sanford
Poster
2024 ASCO Genitourinary Cancers Symposium
Weight variation during androgen deprivation therapy in patients with localized prostate cancer: Data from two prospective randomized trials.
First Author: Abdenour Nabid
Poster
2018 Cancer Survivorship Symposium
Androgen deprivation therapy (ADT) and cardiovascular mortality (CVD) in men with early-stage prostate cancer (PC) receiving curative radiation therapy (RT).
First Author: Ashley Hanlon
Poster
2017 Genitourinary Cancers Symposium
A comparison of surrogate endpoints for all cause mortality in men with localized unfavorable-risk prostate cancer.
First Author: Trevor Joseph Royce